Eplerenone for Central Serous Chorioretinopathy: Is There Still Room for This Treatment?

Biomedicines · 2026 · PMC12938718 · PMID 41751267

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

There was a statistically significant improvement in BCVA at 6 months ( p < 0.001) and 12 months ( p < 0.001) in the eplerenone group, while in the control group, there was an improvement in BCVA at 6 months ( p = 0.079) and 12 months ( p = 0.259), which did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.